New England Journal of Medicine· 2012Q1· Clinical trial

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger et al.

12,708citations
Q1SCImago
2012year

Short summary

An anti-PD-1 antibody demonstrated objective responses in up to 28% of patients with advanced melanoma, non-small-cell lung cancer, or renal-cell cancer, with durable responses observed in a significant portion.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine